ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2661

Metformin Combined with Conventional Therapy Increases Absolute Number of Regulatory T Cells in Patients with Systemic Lupus Erythematosus

Meihua Hao1, Zhaoyun Liang2, Xiaona Jing2, Chong Gao3, Xiao-Feng Li4 and Junwei Chen2, 1The second Hospital of Shanxi Medical University, TaiYuan, China, 2The Second Hospital of Shanxi Medical University, Taiyuan, China, 3Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, Cambridge, MA, 4Rheumatology, the Second Hospital of Shanxi Medical University, Taiyuan, China

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: SLE and T-Regulatory Cells

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, October 23, 2018

Title: Systemic Lupus Erythematosus – Clinical Poster III: Treatment

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:To observe the clinical efficacy of metformin in the treatment of SLE and regulation of CD4+ Treg and Th17 cells.

Methods:Thirty-one patients with SLE, fulfilled the ACR 1997 standard, were enrolled in this study. Their average age was37.21±15.65 years, and disease duration was 58.33±56.48 months. They were administered with metformin£¨MET£©£¨250mg Bid£©combined with conventional therapy for 12 weeks. At week 0, week 6 and week 12, the absolute numbers of Th17 and Treg cells were assayed by flow cytometry and SLEDAI score and drug doses were collected.

Results:At week 0, 6 or 12 after metformin treatment combined with conventional therapy, the absolute number of Treg cells in 31 patients was 25.41£¨£©,25.78£¨£©(P=0.054), or 21.09,while that of Th17 cells was 5.96£¨£©,5.60£¨£©, or 4.56£¨£©. The dosage of prednisone in SLE patients was decreased from 16(28.0)mg/d to 11.15(28.10) mg/d (P=0.019) or6.5(19.5)mg/d (P=0.003). 

Conclusion:Our findings suggest that metformin can effectively up-regulate Treg cells as well as increase Th17 cells in a short time and can reduce the usage of prednisone.


Disclosure: M. Hao, None; Z. Liang, None; X. Jing, None; C. Gao, None; X. F. Li, None; J. Chen, None.

To cite this abstract in AMA style:

Hao M, Liang Z, Jing X, Gao C, Li XF, Chen J. Metformin Combined with Conventional Therapy Increases Absolute Number of Regulatory T Cells in Patients with Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/metformin-combined-with-conventional-therapy-increases-absolute-number-of-regulatory-t-cells-in-patients-with-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/metformin-combined-with-conventional-therapy-increases-absolute-number-of-regulatory-t-cells-in-patients-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology